Prilenia Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 32

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $53M

  • Investors
  • 11

Prilenia General Information

Description

Operator of a clinical biotechnology company intended for the treatment of neurodegenerative and neurodevelopmental disorders associated with patients. The company offers a first-in-class oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children, enabling healthcare institutions to maintain functional capacity in early hemodialysis patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Gooimeer 2-35
  • 1411 HD Naarden
  • Netherlands
+31 035
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Gooimeer 2-35
  • 1411 HD Naarden
  • Netherlands
+31 035

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Prilenia Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 12-Apr-2022 $53M Completed Clinical Trials - Phase 3
2. Early Stage VC (Series A) 03-Jun-2020 Completed Clinical Trials - Phase 3
1. Early Stage VC $16M $16M Completed Startup
To view Prilenia’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Prilenia Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical biotechnology company intended for the treatment of neurodegenerative and neurodevelopmental diso
Drug Discovery
Naarden, Netherlands
32 As of 2024

Melbourne, Australia
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Prilenia Competitors (100)

One of Prilenia’s 100 competitors is Mesoblast, a Corporation company based in Melbourne, Australia.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Mesoblast Corporation Melbourne, Australia
Aquinnah Venture Capital-Backed Cambridge, MA
Minerva Neurosciences Formerly VC-backed Burlington, MA
Neurona Therapeutics Formerly VC-backed South San Francisco, CA
Centrose Venture Capital-Backed Madison, WI
You’re viewing 5 of 100 competitors. Get the full list »

Prilenia Patents

Prilenia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026038220-A1 Taste-masked pridopidine formulations, method of use thereof and process for preparation thereof Pending 15-Aug-2024
WO-2025181805-A1 Pridopidine and sigma 2 antagonist agent for treating huntington disease and symptoms thereof Pending 27-Feb-2024
AU-2025210321-A1 Method of prolonging the survival of a subject with als Pending 18-Jan-2024
WO-2025154076-A1 Method of prolonging the survival of a subject with als Pending 18-Jan-2024
US-20260207575-A1 Pridopidine for the treatment of juvenile huntington disease Pending 27-Dec-2022 A61K31/451
To view Prilenia’s complete patent history, request access »

Prilenia Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Prilenia Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Amplitude Ventures Venture Capital Minority
Landa Ventures Corporate Venture Capital Minority
Morningside Group Venture Capital Minority
Sands Capital Growth/Expansion Minority
SV Health Investors PE/Buyout Minority
You’re viewing 5 of 11 investors. Get the full list »

Prilenia FAQs

  • When was Prilenia founded?

    Prilenia was founded in 2018.

  • Where is Prilenia headquartered?

    Prilenia is headquartered in Naarden, Netherlands.

  • What is the size of Prilenia?

    Prilenia has 32 total employees.

  • What industry is Prilenia in?

    Prilenia’s primary industry is Drug Discovery.

  • Is Prilenia a private or public company?

    Prilenia is a Private company.

  • What is Prilenia’s current revenue?

    The current revenue for Prilenia is .

  • How much funding has Prilenia raised over time?

    Prilenia has raised $138M.

  • Who are Prilenia’s investors?

    Amplitude Ventures, Landa Ventures, Morningside Group, Sands Capital, and SV Health Investors are 5 of 11 investors who have invested in Prilenia.

  • Who are Prilenia’s competitors?

    Mesoblast, Aquinnah, Minerva Neurosciences, Neurona Therapeutics, and Centrose are some of the 100 competitors of Prilenia.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process